Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill

Andrew Powaleny   |     June 14, 2018   |   SHARE THIS

This week, the new era of medicine was brought to Capitol Hill in Washington, DC when 55 biopharmaceutical researchers from 20 PhRMA member companies held 79 meetings with members of Congress and their staff. Conversations focused on the life-saving work researchers do each and every day to bring new treatments and cures to patients. During their meetings, researchers shared their own personal stories about the motivation behind their research, and discussed the highs and lows of the drug development process.

Although there are nearly 7,000 medicines in development, only 10 to 12 percent of medicines that enter clinical trials are ultimately approved for use. The odds of getting a medicine from the lab to a patient are tough. Despite these odds, there’s also tremendous hope in the promise of the biopharmaceutical pipeline. Today, 74 percent of medicines in clinical development are potentially first-in-class medicines, meaning they represent a possible new pharmacological class for treating a medical condition. And in cancer alone, new treatment options are changing the trajectory of disease and there are now over 1,100 medicines and vaccines in development to treat the conditions which make up the disease. 


America’s biopharmaceutical researchers work tirelessly to develop treatments that have never existed before. Beyond the scientific advances, the biopharmaceutical industry supports over 4.7 million high-skilled  jobs and is the single largest funder of business research and development, higher than the National Institutes of Health.

By highlighting the research and scientific impact of the biopharmaceutical industry, these researchers brought to life the important work done across the country every day to provide patients with the hope for cures for even the most devastating diseases.



Andrew Powaleny

Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organization's scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.

Topics: New Era of Medicine

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates